Literature DB >> 24049425

Aclidinium bromide inhalation powder (tudorza): a long-acting anticholinergic for the management of chronic obstructive pulmonary disease.

Michele Pisano, Nissa Mazzola.   

Abstract

Aclidinium bromide inhalation powder (Tudorza) for COPD.

Entities:  

Year:  2013        PMID： 24049425      PMCID： PMC3776488     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  6 in total

Review 1.  Chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

2.  Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

Authors:  Rainard Fuhr; Helgo Magnussen; Kristina Sarem; Anna Ribera Llovera; Anne-Marie Kirsten; Meritxell Falqués; Cynthia F Caracta; Esther Garcia Gil
Journal:  Chest       Date:  2011-09-08       Impact factor: 9.410

3.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Authors:  Paul W Jones; Dave Singh; Eric D Bateman; Alvar Agusti; Rosa Lamarca; Gonzalo de Miquel; Rosa Segarra; Cynthia Caracta; Esther Garcia Gil
Journal:  Eur Respir J       Date:  2012-03-22       Impact factor: 16.671

4.  Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

Authors:  Jørgen Vestbo; Claus Vogelmeier; Jacques Creemers; Meritxell Falques; Anna Ribera; Esther Garcia Gil
Journal:  COPD       Date:  2010-10       Impact factor: 2.409

5.  Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Authors:  Edward M Kerwin; Anthony D D'Urzo; Arthur F Gelb; Hassan Lakkis; Esther Garcia Gil; Cynthia F Caracta
Journal:  COPD       Date:  2012-02-09       Impact factor: 2.409

Review 6.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.